Loading clinical trials...

A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes | Clinical Trials | Clareo Health

COMPLETED

A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes

Multi-country Non-interventional Study on the Effectiveness of Empagliflozin in Adult Patients With Type 2 Diabetes in Europe and Asia.

NCT03817463•Boehringer Ingelheim

View on ClinicalTrials.gov

Summary

Non-interventional, multi-country cohort study using existing data and including adults (≥18 years) with a diagnosis of Type 2 diabetes mellitus.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Dispensation or any other record of empagliflozin, any SGLT-2 inhibitor, or any DPP-4 inhibitor use during the study period
•No dispensation or any other record of any other SGLT-2 inhibitor or DPP-4 inhibitor use during the preceding 12 months including at index date
•Having a diagnosis of T2DM before the index date, based on ICD-10 codes or other available data

Exclusion Criteria

•Aged \<18 years on the first dispensation date or date of the first record of empagliflozin, any SGLT-2 inhibitor or any DPP-4 inhibitor use
•Type 1 diabetes mellitus
•Secondary diabetes
•Gestational diabetes
•Having a diagnosis of ESRD during the 12 months before the index date
•\<12 months of available data before the index date, and/or no complete history of drug dispensations/other records of the drug use during this period
•Missing or ambiguous data on age or sex

Locations (13)

Steno Diabetes Center Copenhagen, Department of Clinical Epidemiology

Gentofte Municipality, Denmark

Helsinki University Hospital

Helsinki, Finland

University of Ulm, Institute for Epidemiology and medical biometry

Ulm, Germany

Maccabi Healthcare Services

Tel Aviv, Israel

Gifu University

Gifu, Japan

Oslo University Hospital, Department of Clinical Lipidology

Oslo, Norway

Oslo University Hospital, Department of Cardiology

Oslo, Norway

Ajou University Hospital

Suwon, South Korea

Instituto de Investigación Sanitaria INCLIVA

Valencia, Spain

TFS Trial Form Support International AB

Lund, Sweden

Key Dates

Start Date

April 15, 2019

Primary Completion Date

December 10, 2021

Completion Date

December 10, 2021

Last Updated

September 23, 2024

Enrollment

327,624

ACTUAL participants

Conditions

Diabetes Mellitus, Type 2

Interventions

Subjects treated with Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor

DRUG

Subjects treated with Dipeptidyl peptidase-4 (DPP-4) inhibitor

DRUG

PATHS-UP Health Behavior Self-monitoring Mobile App for Adolescents

NCT06959901

Obesity and Diabetes Mellitus, Type 2Diabetes Prevention

View study

RECRUITINGNA

Michigan Men's Diabetes Project III(MenDIII): Mind and Motion

NCT06574035

Diabetes Mellitus, Type 2Depressive Symptoms+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 23, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes

Inclusion Criteria

Exclusion Criteria

PATHS-UP Health Behavior Self-monitoring Mobile App for Adolescents

Michigan Men's Diabetes Project III(MenDIII): Mind and Motion

Effects of Vitamin D3 and Yeast Beta-Glucan Supplementation on Glycemic Control and Cardiovascular Disease Risk in Patients With Type 2 Diabetes

Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use

Prediction of Heart Failure and Cognitive Decline in Type 2 Diabetes

Implementing Scalable, PAtient-centered, Team-based, Technology-enabled Care for Adults With Type 2 Diabetes (iPATH)